S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row

Twist Bioscience (TWST) Stock Forecast, Price & News

$20.34
+0.66 (+3.35%)
(As of 09/22/2023 ET)
Compare
Today's Range
$19.42
$20.48
50-Day Range
$18.62
$26.57
52-Week Range
$11.46
$40.50
Volume
673,997 shs
Average Volume
911,644 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.67

Twist Bioscience MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
40.9% Upside
$28.67 Price Target
Short Interest
Bearish
24.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.73) to ($3.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

617th out of 963 stocks

Biological Products, Except Diagnostic Industry

97th out of 158 stocks


TWST stock logo

About Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

TWST Price History

TWST Stock News Headlines

WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Barclays Sticks to Its Buy Rating for Twist Bioscience (TWST)
Twist Bioscience Corp Q3 Loss decreases, beats estimates
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Twist Bioscience Stock Soars After Q3 Report - Here's Why
Twist Bioscience's Earnings Outlook
Synthetic biology pioneer Twist to cut 212 jobs
Reconsidering Twist Biosciences
Analyst Ratings for Twist Bioscience
Earnings Preview: Twist Bioscience
See More Headlines
Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Company Calendar

Last Earnings
8/04/2023
Today
9/24/2023
Fiscal Year End
9/30/2023
Next Earnings (Estimated)
11/17/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TWST
Fax
N/A
Employees
989
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.67
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+40.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-217,860,000.00
Pretax Margin
-88.26%

Debt

Sales & Book Value

Annual Sales
$203.57 million
Book Value
$14.01 per share

Miscellaneous

Free Float
50,623,000
Market Cap
$1.17 billion
Optionable
Not Optionable
Beta
1.28
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Emily Marine Leproust Ph.D. (Age 49)
    Co-Founder, Chairman & CEO
    Comp: $1.4M
  • Dr. Patrick John Finn Ph.D. (Age 51)
    Pres & COO
    Comp: $801.78k
  • Mr. James M. ThorburnMr. James M. Thorburn (Age 67)
    CFO & Principal Accounting Officer
    Comp: $815.16k
  • Mr. Dennis Cho (Age 52)
    Sr. VP, Gen. Counsel, Sec. and Chief Ethics & Compliance Officer
    Comp: $537.93k
  • Dr. William Charles Banyai Ph.D. (Age 68)
    Sr. VP of Advanced Devel., GM of Data Storage & Director
    Comp: $745.64k
  • Mr. Robert F. Werner (Age 50)
    Chief Accounting Officer
  • Mr. Siyuan Chen
    Chief Technology Officer
  • Dr. Aaron K. Sato Ph.D.
    Chief Scientific Officer
  • Mr. Chet Gandhi
    Chief Information Officer
  • Ms. Paula GreenMs. Paula Green (Age 55)
    Sr. VP of HR













TWST Stock - Frequently Asked Questions

Should I buy or sell Twist Bioscience stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TWST shares.
View TWST analyst ratings
or view top-rated stocks.

What is Twist Bioscience's stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price targets for Twist Bioscience's stock. Their TWST share price forecasts range from $20.00 to $36.00. On average, they anticipate the company's share price to reach $28.67 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price.
View analysts price targets for TWST
or view top-rated stocks among Wall Street analysts.

How have TWST shares performed in 2023?

Twist Bioscience's stock was trading at $23.81 at the start of the year. Since then, TWST stock has decreased by 14.6% and is now trading at $20.34.
View the best growth stocks for 2023 here
.

When is Twist Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 17th 2023.
View our TWST earnings forecast
.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) released its quarterly earnings results on Friday, August, 4th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.13. The company earned $63.80 million during the quarter, compared to analyst estimates of $60.62 million. Twist Bioscience had a negative trailing twelve-month return on equity of 29.09% and a negative net margin of 88.97%. The firm's quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.08) EPS.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience updated its fourth quarter 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $63.00 million-$64.00 million, compared to the consensus revenue estimate of $62.25 million.

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (12.18%), BlackRock Inc. (12.03%), JPMorgan Chase & Co. (8.95%), State Street Corp (8.45%), William Blair Investment Management LLC (6.30%) and Sumitomo Mitsui Trust Holdings Inc. (6.24%). Insiders that own company stock include Dennis Cho, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends
.

How do I buy shares of Twist Bioscience?

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $20.34.

How much money does Twist Bioscience make?

Twist Bioscience (NASDAQ:TWST) has a market capitalization of $1.17 billion and generates $203.57 million in revenue each year. The company earns $-217,860,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis.

How many employees does Twist Bioscience have?

The company employs 989 workers across the globe.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.

This page (NASDAQ:TWST) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -